ARCH Venture Management as of March 31, 2024
Portfolio Holdings for ARCH Venture Management
ARCH Venture Management holds 8 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Verve Therapeutics (VERV) | 33.2 | $27M | 2.0M | 13.28 | |
| Erasca (ERAS) | 28.4 | $23M | 11M | 2.06 | |
| Gossamer Bio (GOSS) | 11.8 | $9.5M | 8.1M | 1.18 | |
| Denali Therapeutics (DNLI) | 9.7 | $7.8M | 381k | 20.52 | |
| Q32 Bio | 6.8 | $5.5M | 321k | 17.04 | |
| Cero Therapeutics Holdings Class A Com (CERO) | 5.5 | $4.4M | 1.4M | 3.07 | |
| Singular Genomics Systems In (OMIC) | 2.4 | $2.0M | 3.8M | 0.51 | |
| Unity Biotechnology (UBX) | 2.1 | $1.6M | 1.0M | 1.64 |
